Prevention
Prevention of chemotherapy-induced peripheral neuropathy
Recommendation 1.1
➤ Clinicians should assess the risks and benefits of agents known to cause
CIPN among patients with underlying neuropathy and with conditions
that predispose to neuropathy such as diabetes and/or a family or
personal history of hereditary neuropathy. (Moderate recommendation;
IC-B-L)
Recommendation 1.2
➤ Clinicians should not offer, and should discourage use of, acetyl-
L-carnitine for the prevention of CIPN in cancer patients. (Strong
recommendation; EB-H-H)
Recommendation 1.3
➤ Outside the context of a clinical trial, no recommendations can be made
on the use of the following interventions for the prevention of CIPN:
• Acupuncture
• Cryotherapy
• Compression therapy
• Exercise therapy
• Ganglioside-monosialic acid (GM-1)
(No recommendation; L)
Note: While preliminary evidence suggests a potential for benefit from these interventions,
larger sample-sized definitive studies are needed to confirm efficacy and clarify risks.
